Study title: Morning Lantus® (insulin glargine [rDNA origin] injection) vs. intermediateacting insulin twice daily as basal insulin in a multiple daily injection regimen with Humalog® (insulin lispro injection [rDNA Origin]) in pediatrics with type 1 diabetes mellitus: an activeontrolled, open, randomized, gender-stratified, two arm, parallel-group study.
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Endocrine System Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: INSULIN GLARGINE | |||||
| ATC code: A10AE04 | |||||
| Document link: | |||||
| Document date: 2011-09-23 | |||||
| Study number: HOE901/4030 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |